CoChat

Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach

Open access
Madeddu, Clelia, Gramignano, Giulia, Astara, Giorgio, Demontis, Roberto, Sanna, Elisabetta, Atzeni, Vinicio, Macciò, Antonio · 2018 · Frontiers in Physiology
Cited by 201

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Cancer-related anemia (CRA) is a common sign occurring in more than 30% of cancer patients at diagnosis before the initiation of antineoplastic therapy. CRA has a relevant influence on survival, disease progression, treatment efficacy, and the patients' quality of life. It is more often detected in patients with advanced stage disease, where it represents a specific symptom of the neoplastic disease, as a consequence of chronic inflammation. In fact, CRA is characterized by biological and hematologic features that resemble those described in anemia associated to chronic inflammatory disease. Proinflammatory cytokine, mainly IL-6, which are released by both tumor and immune cells, play a pivotal action in CRA etiopathogenesis: they promote alterations in erythroid progenitor proliferation, erythropoietin (EPO) production, survival of circulating erythrocytes, iron balance, redox status, and energy metabolism, all of which can lead to anemia. The discovery of hepcidin allowed a greater knowledge of the relationships between immune cells, iron metabolism, and anemia in chronic inflammatory diseases. Additionally, chronic inflammation influences a compromised nutritional status, which in turn might induce or contribute to CRA. In the present review we examine the multifactorial pathogenesis of CRA discussing the main and novel mechanisms by which immune, nutritional, and metabolic components affect its onset and severity. Moreover, we analyze the status of the art and the perspective for the treatment of CRA. Notably, despite the high incidence and clinical relevance of CRA, controlled clinical studies testing the most appropriate treatment for CRA are scarce, and its management in clinical practice remains challenging. The present review may be useful to indicate the development of an effective approach based on a detailed assessment of all factors potentially involved in the pathogenesis of CRA. This mechanism-based approach is essential for clinicians to plan a safe, targeted, and successful therapy, thereby promoting a relevant amelioration of patients' quality of life.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphys.2018.01294

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 186

  1. Aapro, 2009, Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events., Br. J. Cancer., 101, 1961, 10.1038/sj.bjc.6605255 · DOI
  2. Abella, 2017, Leptin in the interplay of inflammation, metabolism and immune system disorders., Nat. Rev. Rheumatol., 13, 100, 10.1038/nrrheum.2016.209 · DOI · Paper page
  3. Adamson, 2008, The anemia of inflammation/malignancy: mechanisms and management., Hematol. Am. Soc. Hematol. Educ. Program, 2008, 159, 10.1182/asheducation-2008.1.159 · DOI · Paper page
  4. Alvarez-Hernandez, 1989, Induction of hypoferremia and modulation of macrophage iron metabolism by tumor necrosis factor., Lab. Invest., 61, 319
  5. An, 2015, T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy., World J. Surg. Oncol., 13, 10.1186/s12957-015-0488-7 · DOI
  6. Argilés, 2014, Cancer cachexia: understanding the molecular basis., Nat. Rev. Cancer, 14, 754, 10.1038/nrc3829 · DOI · Paper page
  7. Auerbach, 2004, Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial., J. Clin. Oncol., 22, 1301, 10.1200/JCO.2004.08.119 · DOI · Paper page
  8. Axelsson, 2005, Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD., Am. J. Kidney Dis., 46, 628, 10.1053/j.ajkd.2005.06.004 · DOI
  9. Baribeault, 2011, Iron replacement therapy in cancer-related anemia., Am. J. Health Syst. Pharm., 68, S4, 10.2146/ajhp110039 · DOI
  10. Basseri, 2012, Hepcidin is a key mediator of anemia of inflammation in Crohn’s disease., J. Crohns Colitis, 7, e286, 10.1016/j.crohns.2012.10.013 · DOI · Paper page
  11. Bastit, 2008, Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia., J. Clin. Oncol., 26, 1611, 10.1200/JCO.2006.10.4620 · DOI · Paper page
  12. Bayliss, 2011, A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer., Expert. Opin. Biol. Ther., 11, 1663, 10.1517/14712598.2011.627850 · DOI · Paper page
  13. Beguin, 1998, Prediction of response to optimize outcome of treatment with erythropoietin., Semin. Oncol., 25, 27
  14. Benedik, 2014, The physiologic role of erythrocytes in oxygen delivery and implications for blood storage., Crit. Care Nurs. Clin. North Am., 26, 325, 10.1016/j.ccell.2014.04.002 · DOI
  15. Bennett, 2008, Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia., JAMA, 299, 914, 10.1001/jama.299.8.914 · DOI · Paper page
  16. Bennett, 1981, Homeostatic removal of senescent murine erythrocytes by splenic macrophages., Exp. Hematol., 9, 297
  17. Bertero, 1997, Anemia of chronic disorders in systemic autoimmune diseases., Haematologica, 82, 375
  18. Bing, 2006, Adipose atrophy in cancer cachexia: morphologic and molecular analysis of adipose tissue in tumour-bearing mice., Br. J. Cancer, 95, 1028, 10.1038/sj.bjc.6603360 · DOI · Paper page
  19. Birgegård, 2005, Cancer-related anemia: pathogenesis, prevalence and treatment., Oncology, 68, 3, 10.1159/000083128 · DOI · Paper page
  20. Bistrian, 2000, Impact of inflammation on nutrition, iron status, and erythropoietin responsiveness in ESRD patients., Nephrol. Nurs. J., 27, 616
  21. Blackwell, 2004, rHuEPO and improved treatment outcomes: potential modes of action., Oncologist, 9, 41, 10.1634/theoncologist.9-90005-41 · DOI
  22. Bogdanos, 2004, Epoetin beta (NeoRecormon) corrects anaemia in patients with hormone-refractory prostate cancer and bone metastases., Anticancer Res., 24, 1957
  23. Bohlius, 2009, Erythropoietin or Darbepoetin for patients with cancer–meta-analysis based on individual patient data., Cochrane Database Syst. Rev., 3, 10.1002/14651858.CD007303.pub2 · DOI
  24. Bohlius, 2014, Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data., Br. J. Cancer, 111, 33, 10.1038/bjc.2014.171 · DOI
  25. Bohlius, 2006, Cancer-related anemia and recombinant human erythropoietin–an updated overview., Nat. Clin. Pract. Oncol., 3, 152, 10.1038/ncponc0451 · DOI
  26. Boushel, 2017, Linking skeletal muscle blood flow and metabolism to the limits of human performance., Appl. Physiol. Nutr. Metab., 42, 111, 10.1139/apnm-2016-0393 · DOI
  27. Bron, 2001, Biological basis of anemia., Semin. Oncol., 28, 1, 10.1016/S0093-7754(01)90205-2 · DOI
  28. Brown, 2010, Assessment of fatigue after blood transfusion in palliative care patients: a feasibility study., J. Palliat. Med., 13, 1327, 10.1089/jpm.2010.0143 · DOI
  29. Brown, 2007, Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity., Stem Cells, 25, 718, 10.1634/stemcells.2006-0687 · DOI
  30. Buemi, 2003, The pleiotropic effects of erythropoietin in the central nervous system., J. Neuropathol. Exp. Neurol., 62, 228, 10.1093/jnen/62.3.228 · DOI
  31. Bukowska, 2015, Oxidative stress and damage to erythrocytes in patients with chronic obstructive pulmonary disease–changes in ATPase and acetylcholinesterase activity., Biochem. Cell. Biol., 93, 574, 10.1139/bcb-2015-0066 · doi:10.1139/bcb-2015-0066
  32. Burke, 2015, IL-1β reciprocally regulates chemokine and insulin secretion in pancreatic β-cells via NF-κB., Am. J. Physiol. Endocrinol. Metab., 309, E715, 10.1152/ajpendo.00153.2015 · DOI
  33. Camaschella, 2008, Recent advances in the understanding of inherited sideroblastic anaemia., Br. J. Haematol., 143, 27, 10.1111/j.1365-2141.2008.07290.x · DOI
  34. Camaschella, 2016, The mutual control of iron and erythropoiesis., Int. J. Lab. Hematol., 38, 20, 10.1111/ijlh.12505 · DOI · Paper page
  35. Carbó, 1994, Anti-tumour necrosis factor-alpha treatment interferes with changes in lipid metabolism in a tumour cachexia model., Clin. Sci., 87, 349, 10.1042/cs0870349 · doi:10.1042/cs0870349
  36. Caro, 2001, Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review., Cancer, 91, 2214, 10.1002/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P · DOI · Paper page
  37. Carson, 2016, Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage., JAMA, 316, 2025, 10.1001/jama.2016.9185 · DOI · Paper page
  38. Cawthorn, 2008, TNF-α and adipocyte biology., FEBS Lett., 582, 117, 10.1016/j.febslet.2007.11.051 · DOI · Paper page
  39. Cella, 1998, Factors influencing quality of life in cancer patients: anemia and fatigue., Semin. Oncol., 25, 43
  40. Chamogeorgakis, 2008, Does anemia affect outcome after lobectomy or pneumonectomy in early stage lung cancer patients who have not received neo-adjuvant treatment?, Thorac. Cardiovasc. Surg., 56, 148, 10.1055/s-2007-989455 · doi:10.1055/s-2007-989455
  41. Chiabrando, 2014, Heme and erythropoieis: more than a structural role., Haematologica, 99, 973, 10.3324/haematol.2013.091991 · DOI · Paper page
  42. Christ, 1997, The importance of growth hormone in the regulation of erythropoiesis, red cell mass, and plasma volume in adults with growth hormone deficiency., J. Clin. Endocrinol. Metab., 82, 2985
  43. Chung, 2015, The mTORC1/4E-BP pathway coordinates hemoglobin production with L-leucine availability., Sci. Signal., 8, 10.1126/scisignal.aaa5903 · DOI
  44. Coward, 2011, Interleukin-6 as a therapeutic target in human ovarian cancer., Clin. Cancer Res., 17, 6083, 10.1158/1078-0432.CCR-11-0945 · DOI · Paper page
  45. Crawford, 2002, Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy., Cancer, 95, 888, 10.1002/cncr.10763 · DOI · Paper page
  46. Cybulska, 2017, Indications for and complications of transfusion and the management of gynecologic malignancies., Gynecol. Oncol., 146, 416, 10.1016/j.ygyno.2017.05.010 · DOI
  47. Daneryd, 1998, Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study., Cancer Res., 58, 5374
  48. Delano, 2006, The origins of cachexia in acute and chronic inflammatory diseases., Nutr. Clin. Pract., 21, 68, 10.1177/011542650602100168 · DOI · Paper page
  49. Doty, 2015, Coordinate expression of heme and globin is essential for effective erythropoiesis., J. Clin. Invest., 125, 4681, 10.1172/JCI83054 · DOI
  50. Doulatov, 2012, Hematopoiesis: a human perspective., Cell Stem Cell, 10, 120, 10.1016/j.stem.2012.01.006 · DOI · Paper page
  51. Dunn, 2003, Anemia at the end of life: prevalence, significance and causes in patients receiving palliative care., J. Pain Symptom Manage., 26, 1132, 10.1016/j.jpainsymman.2003.04.001 · DOI
  52. Faquin, 1992, Effect of inflammatory cytokines on hypoxia-induced erythropoietin production., Blood, 79, 1987, 10.1182/blood.V79.8.1987.1987 · DOI · Paper page
  53. Fearon, 2011, Definition and classification of cancer cachexia: an international consensus., Lancet. Oncol., 12, 489, 10.1016/S1470-2045(10)70218-7 · DOI · Paper page
  54. Fishbane, 2000, The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate., Semin. Dial., 13, 381, 10.1046/j.1525-139x.2000.00104.x · DOI
  55. Friesen, 2015, Modeling the energetic cost of cancer as a result of altered energy metabolism: implications for cachexia., Theor. Biol. Med. Model., 12, 10.1186/s12976-015-0015-0 · DOI
  56. Fuso, 2005, Pretreatment serum hemoglobin level as a predictive factor of response to neoadjuvant chemotherapy in patients with locally advanced squamous cervical carcinoma: a preliminary report., Gynecol. Oncol., 99, S187, 10.1016/j.ygyno.2005.07.079 · doi:10.1016/j.ygyno.2005.07.079
  57. Gaspar, 2015, Anemia in malignancies: pathogenetic and diagnostic considerations., Hematology, 20, 18, 10.1179/1607845414Y.0000000161 · DOI
  58. Gautron, 2010, Neurobiology of inflammation-associated anorexia., Front. Neurosci., 3, 10.3389/neuro.23.003.2009 · DOI
  59. Gleason, 1995, Blood transfusion and its benefits in palliative care., Palliat. Med., 9, 307, 10.1177/026921639500900405 · doi:10.1177/026921639500900405
  60. Goldberg, 2008, FDA orders more changes in ESA label, agents not indicated in curative setting., Cancer Lett., 34, 1
  61. Goodnough, 2005, Risks of blood transfusion., Anesthesiol. Clin. North Am., 23, 241, 10.1016/j.atc.2004.07.004 · doi:10.1016/j.atc.2004.07.004
  62. Gordon, 2008, Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study., Oncologist, 13, 715, 10.1634/theoncologist.2007-0241 · DOI
  63. Grant, 2013, Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment: Comparative Effectiveness Update
  64. Grogan, 1999, The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix., Cancer, 86, 1528, 10.1002/(SICI)1097-0142(19991015)86:8<1528::AID-CNCR20>3.0.CO;2-E · DOI
  65. Haag-Weber, 2012, Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study., Clin. Nephrol., 77, 8, 10.5414/CN107304 · DOI
  66. Hagerty, 2008, Continued regulatory actions affecting the use of erythropoiesis-stimulating agents., J. Oncol. Pract., 4, 267, 10.1200/JOP.0863501 · doi:10.1200/jop.0863501
  67. Halstenson, 1991, Abraham PA. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta., Clin. Pharmacol. Ther., 50, 702, 10.1038/clpt.1991.210 · DOI · Paper page
  68. Hare, 2014, Tolerance of anemia: understanding the adaptive physiological mechanisms which promote survival., Transfus. Apher. Sci., 50, 10, 10.1016/j.transci.2013.12.005 · DOI
  69. Hare, 2008, Anemia and cerebral outcomes: many questions, fewer answers., Anesth. Analg., 107, 1356, 10.1213/ane.0b013e318184cfe9 · DOI
  70. Harrison, 2004, Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?, Oncologist, 9, 31, 10.1634/theoncologist.9-90005-31 · DOI · Paper page
  71. Henke, 2003, Erythropoietin to treat head and neck cancer patients with anaemia undergoing radio-therapy: randomised, double-blind, placebo-controlled trial., Lancet, 362, 1255, 10.1016/S0140-6736(03)14567-9 · DOI · Paper page
  72. Henke, 2006, Do erythropoietin receptors on cancer cells explain unexpected clinical findings?, J. Clin. Oncol., 24, 4708, 10.1200/JCO.2006.06.2737 · DOI · Paper page
  73. Henry, 2010, Parenteral iron therapy in cancer-associated anemia., Hematol. Am. Soc. Hematol. Educ. Program, 2010, 351, 10.1182/asheducation-2010.1.351 · doi:10.1182/asheducation-2010.1.351
  74. Henry, 2007, Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy., Oncologist, 12, 231, 10.1634/theoncologist.12-2-231 · DOI · Paper page
  75. Höckel, 2001, Biological consequences of tumor hypoxia., Semin. Oncol., 28, 36, 10.1016/S0093-7754(01)90211-8 · DOI · Paper page
  76. Hung, 2005, High-calorie supplementation increases serum leptin levels and improves response to rHuEPO in long-term hemodialysis patients., Am. J. Kidney Dis., 45, 1073, 10.1053/j.ajkd.2005.02.020 · DOI
  77. Iglesias, 1998, Recombinant human growth hormone therapy in malnourished dialysis patients: a randomized controlled study., Am. J. Kidney Dis., 32, 454, 10.1053/ajkd.1998.v32.pm9740162 · DOI
  78. Jelkmann, 1992, Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys., Life Sci., 50, 301, 10.1016/0024-3205(92)90338-P · DOI · Paper page
  79. Jelkmann, 2010, Biosimilar epoetins and other “follow-on” biologics: update on the European experiences., Am. J. Hematol., 85, 771, 10.1002/ajh.21805 · DOI
  80. Jewell, 2001, Induction of HIF-1 alpha in response to hypoxia is instantaneous., FASEB J., 15, 1312, 10.1096/fj.00-0732fje · DOI · Paper page
  81. Juneja, 2008, Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer., Clin. Cancer Res., 14, 3242, 10.1158/1078-0432.CCR-07-1872 · doi:10.1158/1078-0432.ccr-07-1872
  82. Kader, 2007, Prognostic significance of blood transfusions in patients with esophageal cancer treated with combined chemoradiotherapy., Am. J. Clin. Oncol., 30, 492, 10.1097/01.coc.0000264177.66369.18 · doi:10.1097/01.coc.0000264177.66369.18
  83. Kalantar-Zadeh, 2001, A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients., Am. J. Kidney Dis., 38, 1251, 10.1053/ajkd.2001.29222 · DOI · Paper page
  84. Katz, 2007, Neumann D. Erythropoietin enhances immune responses in mice., Eur. J. Immunol., 37, 1584, 10.1002/eji.200637025 · DOI · Paper page
  85. Khorana, 2008, Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer., Arch. Intern. Med., 168, 2377, 10.1001/archinte.168.21.2377 · DOI · Paper page
  86. Kling, 1996, Iron deprivation increases erythropoietin production in vitro, in normal subjects and patients with malignancy., Br. J. Haematol., 95, 241, 10.1046/j.1365-2141.1996.d01-1919.x · DOI
  87. Ladányi, 2004, T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma., Clin. Cancer Res., 10, 521, 10.1158/1078-0432.CCR-1161-03 · DOI · Paper page
  88. Lang, 2014, Oxidative stress and suicidal erythrocyte death., Antioxid. Redox Signal., 21, 138, 10.1089/ars.2013.5747 · DOI · Paper page
  89. Leyland–Jones, 2005, Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study., J. Clin. Oncol., 23, 5960, 10.1200/JCO.2005.06.150 · DOI · Paper page
  90. Lindholm, 2004, Effects of recombinant erythropoietin in palliative treatment of unselected cancer patients., Clin. Cancer Res., 10, 6855, 10.1158/1078-0432.CCR-04-0373 · DOI
  91. Ludwig, 2009, Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study., Eur. J. Cancer, 45, 1603, 10.1016/j.ejca.2009.02.003 · DOI
  92. Ludwig, 2001, Symptomatology of anemia., Semin. Oncol., 28, 7, 10.1016/S0093-7754(01)90206-4 · DOI · Paper page
  93. Ludwig, 2004, The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients., Eur. J. Cancer, 40, 2293, 10.1016/j.ejca.2004.06.019 · DOI · Paper page
  94. Lundholm, 2004, Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: effects on survival, metabolism, and function., Cancer, 100, 1967, 10.1002/cncr.20160 · DOI · Paper page
  95. Macciò, A multitargeted treatment approach for anemia and cachexia in metastatic castration-resistant prostate cancer., J. Pain Symptom Manage., 50, e1, 10.1016/j.jpainsymman.2015.04.014 · doi:10.1016/j.jpainsymman.2015.04.014
  96. Macciò, Surprising results of a supportive integrated therapy in myelofibrosis., Nutrition, 31, 239, 10.1016/j.nut.2014.07.016 · doi:10.1016/j.nut.2014.07.016
  97. Macciò, The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study., Haematologica, 100, 124, 10.3324/haematol.2014.112813 · DOI · Paper page
  98. Macciò, 1998, High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer., Gynecol. Oncol., 69, 248, 10.1006/gyno.1998.4974 · DOI
  99. Macciò, 2012, Inflammation and ovarian cancer., Cytokine, 58, 133, 10.1016/j.cyto.2012.01.015 · DOI · Paper page
  100. Macciò, 2012, A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life., Gynecol. Oncol., 124, 417, 10.1016/j.ygyno.2011.12.435 · DOI
  101. Macciò, 2010, Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-β for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study., Oncologist, 15, 894, 10.1634/theoncologist.2010-0020 · DOI
  102. Macciò, 2009, Interleukin-6 and leptin as markers of energy metabolic changes in advanced ovarian cancer patients., J. Cell. Mol. Med., 13, 3951, 10.1111/j.1582-4934.2008.00408.x · DOI
  103. Madeddu, 2014, Role of inflammation and oxidative stress in post-menopausal oestrogen-dependent breast cancer., J. Cell. Mol. Med., 18, 2519, 10.1111/jcmm.12413 · DOI
  104. Madeddu, 2018, Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related anemia in advanced ovarian cancer: key role of Interleukin-6., Haematologica, 10.3324/haematol.2018.191551 · DOI
  105. Madeddu, 2015, Muscle wasting as main evidence of energy impairment in cancer cachexia: future therapeutic approaches., Future Oncol., 10.2217/fon.15.195 · DOI
  106. Mantovani, 2003, Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress., J. Mol. Med., 81, 664, 10.1007/s00109-003-0476-1 · DOI
  107. Mantovani, 2001, Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites., J. Mol. Med., 79, 406, 10.1007/s001090100234 · DOI
  108. Marini, 2017, A polymorphism at IGF1 locus is associated with anemia., Oncotarget, 8, 32398, 10.18632/oncotarget.16132 · DOI
  109. Martin, 2015, Diagnostic criteria for the classification of cancer-associated weight loss., J. Clin. Oncol., 33, 90, 10.1200/JCO.2014.56.1894 · DOI · Paper page
  110. McCammon, 2003, Global transcription analysis of Krebs tricarboxylic acid cycle mutants reveals an alternating pattern of gene expression and effects on hypoxic and oxidative genes., Mol. Biol. Cell., 14, 958, 10.1091/mbc.e02-07-0422 · DOI · Paper page
  111. McCranor, 2014, Interleukin-6 directly impairs the erythroid development of human TF-1 erythroleukemic cells., Blood Cells Mol. Dis., 52, 126, 10.1016/j.bcmd.2013.09.004 · DOI
  112. McMillan, 2009, Systemic inflammation, nutritional status and survival in patients with cancer., Curr. Opin. Clin. Nutr. Metab. Care, 12, 223, 10.1097/MCO.0b013e32832a7902 · DOI · Paper page
  113. Means, 1995, Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia., Stem Cells, 13, 32, 10.1002/stem.5530130105 · DOI · Paper page
  114. Means, 2003, Recent developments in the anemia of chronic disease., Curr. Hematol. Rep., 2, 116
  115. Mercadante, 2009, Effects of red blood transfusion on anemia-related symptoms in patients with cancer., J. Palliat. Med., 12, 60, 10.1089/jpm.2008.0139 · DOI
  116. Mhaskar, 2016, The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis stimulating agents., Cochrane Database Syst. Rev., 2, 10.1002/14651858.CD009624.pub2 · DOI
  117. Michallet, 2016, Biosimilar epoetin zeta in oncology and haematology: development and experience following 6 years of use., Acta Haematol., 135, 44, 10.1159/000438976 · doi:10.1159/000438976
  118. Miller, 2008, Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer., J. Clin. Oncol., 26, 971, 10.1200/JCO.2007.10.7805 · DOI · Paper page
  119. Millonig, 2012, Sustained submicromolar H2O2 levels induce hepcidin via signal transducer and activator of transcription 3 (STAT3)., J. Biol. Chem., 287, 37472, 10.1074/jbc.M112.358911 · DOI · Paper page
  120. Molnar, 2011, Association between the malnutrition-inflammation score and post-transplant anaemia., Nephrol. Dial. Transplant., 26, 2000, 10.1093/ndt/gfq690 · DOI
  121. Montel-Hagen, 2009, Erythroid glucose transporters., Curr. Opin. Hematol., 16, 165, 10.1097/MOH.0b013e328329905c · DOI
  122. Mystakidou, 2005, Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment., Anticancer Res., 25, 3495
  123. Nagasawa, 2005, Pivotal role of peroxisome proliferator-activated receptor gamma (PPARgamma) in regulation of erythroid progenitor cell proliferation and differentiation., Exp. Hematol., 33, 857, 10.1016/j.exphem.2005.05.003 · DOI
  124. Nathan, 2015, Amino acid uptake in erythropoiesis., Sci. Signal., 8, 10.1126/scisignal.aab1203 · doi:10.1126/scisignal.aab1203
  125. Nekoui, 2017, Erythropoietin and nonhematopoietic effects., Am. J. Med. Sci., 353, 76, 10.1016/j.amjms.2016.10.009 · DOI
  126. Newland, 2008, Tumor progression associated with erythropoiesis-stimulating agents., Ann. Pharmacother., 42, 1865, 10.1345/aph.1L231 · doi:10.1345/aph.1l231
  127. Nieken, 1995, Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients., Blood, 86, 900, 10.1182/blood.V86.3.900.900 · DOI · Paper page
  128. Nilsson-Ehle, 2005, Insulin-like growth factor-1 is a predictor of blood haemoglobin concentration in 70-yr-old subjects., Eur. J. Haematol., 74, 111, 10.1111/j.1600-0609.2004.00374.x · DOI
  129. Obermair, 1998, The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients: a prospective review., Cancer, 83, 726, 10.1002/(SICI)1097-0142(19980815)83:4<726::AID-CNCR14>3.0.CO;2-U · DOI
  130. Oburoglu, 2016, Metabolic regulation of hematopoietic stem cell commitment and erythroid differentiation., Curr. Opin. Hematol., 23, 198, 10.1097/MOH.0000000000000234 · DOI
  131. Oburoglu, 2014, Glucose and glutamine metabolism regulate human hematopoietic stem cell lineage specification., Cell Stem Cell, 15, 169, 10.1016/j.stem.2014.06.002 · DOI · Paper page
  132. Olszewska, 2012, Oxidative stress modulates the organization of erythrocyte membrane cytoskeleton., Postepy Hig. Med. Dosw., 66, 534, 10.5604/17322693.1005677 · doi:10.5604/17322693.1005677
  133. Palis, 2014, Primitive and definitive erythropoiesis in mammals., Front. Physiol., 5, 10.3389/fphys.2014.00003 · DOI · Paper page
  134. Patel, 2017, TNF-α and cancer cachexia: molecular insights and clinical implications., Life Sci., 170, 56, 10.1016/j.lfs.2016.11.033 · DOI · Paper page
  135. Patra, 2012, Integrative role of neuropeptides and cytokines in cancer anorexia-cachexia syndrome., Clin. Chim. Acta, 413, 1025, 10.1016/j.cca.2011.12.008 · DOI
  136. Pedrazzoli, 2008, Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha., J. Clin. Oncol., 26, 1619, 10.1200/JCO.2007.12.2051 · DOI · Paper page
  137. Preston, 2012, Blood transfusions for anaemia in patients with advanced cancer., Cochrane Database Syst. Rev., 2, 10.1002/14651858.CD009007.pub2 · DOI
  138. Prince, 2012, Late stage erythroid precursor production is impaired in mice with chronic inflammation., Haematologica, 97, 1648, 10.3324/haematol.2011.053397 · DOI · Paper page
  139. Pronzato, 2006, Cancer-related anaemia management in the 21st century., Cancer Treat. Rev., 32, S1, 10.1016/j.ctrv.2006.04.008 · DOI
  140. Quirt, 2001, Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy., J. Clin. Oncol., 19, 4126, 10.1200/JCO.2001.19.21.4126 · DOI
  141. Rattanasompattikul, 2013, Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients., Nephrol. Dial. Transplant., 28, 1936, 10.1093/ndt/gfs368 · DOI
  142. Reglin, 2009, Structural adaptation of microvessel diameters in response to metabolic stimuli: where are the oxygen sensors?, Am. J. Physiol. Heart Circ. Physiol., 297, H2206, 10.1152/ajpheart.00348.2009 · DOI
  143. Ribeiro, 2016, Pathological and molecular mechanisms underlying resistance to recombinant human erythropoietin therapy in the remnant kidney rat model of chronic kidney disease associated anemia., Biochimie, 125, 150, 10.1016/j.biochi.2016.03.012 · DOI
  144. Rizzo, 2010, American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer., Blood, 116, 4045, 10.1182/blood-2010-08-300541 · DOI · Paper page
  145. Rodgers, 2017, NCCN. Cancer- and Chemotherapy-Induced Anemia, Version 2.2017
  146. Sailaja, 2003, The antioxidant status during maturation of reticulocytes to erythrocytes in type 2 diabetics., Free. Radic. Biol. Med., 35, 133, 10.1016/S0891-5849(03)00071-6 · DOI
  147. Saini, 2006, Waste management - cytokines, growth factors and cachexia., Cytokine Growth Factor Rev., 17, 475, 10.1016/j.cytogfr.2006.09.006 · DOI · Paper page
  148. Sandler, 1990, Interleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vitro., Endocrinology, 126, 1288, 10.1210/endo-126-2-1288 · DOI · Paper page
  149. Sanz Ortiz, 2008, Predictors of response to erythropoiesis-stimulating agents (ESA) in cancer patients: the role of baseline serum epoetin level., Clin. Transl. Oncol., 10, 486, 10.1007/s12094-008-0237-2 · DOI
  150. Schmidt, 2015, Regulation of iron metabolism by hepcidin during conditions of inflammation., J. Biol. Chem., 290, 18975, 10.1074/jbc.R115.650150 · DOI · Paper page
  151. Schwartz, 2007, Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols., Am. J. Health Syst. Pharm., 64, S5, 10.2146/ajhp060601 · DOI
  152. Semenza, 2000, Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1., J. Clin. Invest., 106, 809, 10.1172/JCI11223 · DOI · Paper page
  153. Shasha, 2001, The negative impact of anemia on radiotherapy and chemoradiation outcomes., Semin. Hematol., 38, 8, 10.1016/S0037-1963(01)90125-8 · DOI
  154. Shin, 2014, Prognostic value of pretreatment hemoglobin level in patients with early cervical cancer., Obstet. Gynecol. Sci., 57, 28, 10.5468/ogs.2014.57.1.28 · doi:10.5468/ogs.2014.57.1.28
  155. Shu, 2014, Hepcidin in tumor-related iron deficiency anemia and tumor-related anemia of chronic disease: pathogenic mechanisms and diagnosis., Eur. J. Haematol., 94, 67, 10.1111/ejh.12402 · DOI · Paper page
  156. Simon, 1998, Practice parameter for the use of red blood cell transfusions: developed by the Red Blood Cell Administration Practice Guideline Development Task Force of the College of American Pathologists., Arch. Pathol. Lab. Med., 122, 130
  157. Smith, 2008, Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study., J. Clin. Oncol., 26, 1040, 10.1200/JCO.2007.14.2885 · DOI · Paper page
  158. Spivak, 2000, The blood in systemic disorders., Lancet, 355, 1707, 10.1016/S0140-6736(00)02249-2 · DOI · Paper page
  159. Spivak, 2005, The anaemia of cancer: death by a thousand cuts., Nat. Rev. Cancer, 5, 543, 10.1038/nrc1648 · DOI · Paper page
  160. Spivak, 2011, Iron and the anemia of chronic disease: vindication for the Non-essential role of iron supplementation., Oncology, 25, 421
  161. Spivak, 2009, Anemia management in oncology and hematology., Oncologist, 14, 43, 10.1634/theoncologist.2009-S1-43 · DOI · Paper page
  162. Steensma, 2008, Is anemia of cancer different from chemotherapy-induced anemia?, Clin. Oncol., 26, 1022, 10.1200/JCO.2007.15.3874 · doi:10.1200/jco.2007.15.3874
  163. Steensma, 2011, Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia., J. Clin. Oncol., 29, 97, 10.1200/JCO.2010.30.3644 · DOI · Paper page
  164. Storring, 1998, Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties., Br. J. Haematol., 100, 79, 10.1046/j.1365-2141.1998.00521.x · DOI · Paper page
  165. Strassmann, 1992, Evidence for the involvement of interleukin 6 in experimental cancer cachexia., J. Clin. Invest., 89, 1681, 10.1172/JCI115767 · DOI · Paper page
  166. Succurro, 2011, Low insulin-like growth factor-1 levels are associated with anaemia in adult non-diabetic subjects., Thromb. Haemost., 105, 365, 10.1160/TH10-06-0379 · DOI
  167. Takeda, 2002, Factors contributing to higher hematocrit levels in hemodialysis patients not receiving recombinant human erythropoietin., Am. J. Kidney Dis., 40, 104, 10.1053/ajkd.2002.33918 · DOI
  168. Tanneberger, 2004, Use of red blood cell transfusion in palliative care services: it is still up to date or is cancer-related anemia controlled better with erythropoietic agents?, Ann. Oncol., 15, 839, 10.1093/annonc/mdh178 · doi:10.1093/annonc/mdh178
  169. Tarng, 1999, Erythropoietin hyporesponsiveness: from iron deficiency to iron overload., Kidney Int. Suppl., 69, S107, 10.1038/sj.ki.4490858 · doi:10.1038/sj.ki.4490858
  170. Thomas, 2001, The effect of hemoglobin level on radiotherapy outcomes: the Canadian experience., Semin. Oncol., 28, 60, 10.1016/S0093-7754(01)90215-5 · DOI
  171. Tonia, 2012, Erythropoietin or darbepoetin for patients with cancer., Cochrane Database Syst. Rev., 12, 10.1002/14651858.CD003407.pub5 · DOI · Paper page
  172. Toy, 2005, Transfusion-related acute lung injury: definition and review., Crit. Care Med., 33, 721, 10.1097/01.CCM.0000159849.94750.51 · DOI · Paper page
  173. Tsuboi, 2009, Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, phase III, randomized, double-blind, placebo-controlled study., Jpn. J. Clin. Oncol., 39, 163, 10.1093/jjco/hyn151 · DOI
  174. Tsui, 2014, Differential HIF and NOS responses to acute anemia: defining organ-specific hemoglobin thresholds for tissue hypoxia., Am. J. Physiol. Regul. Integr. Comp. Physiol., 307, R13, 10.1152/ajpregu.00411.2013 · DOI
  175. Turnbull, 1998, Mechanisms of hypothalamic-pituitary-adrenal axis stimulation by immune signals in the adult rat., Ann. N. Y. Acad. Sci., 840, 434, 10.1111/j.1749-6632.1998.tb09582.x · DOI · Paper page
  176. Umemoto, 1997, Leptin stimulates the proliferation of murine myelocytic and primitive hematopoietic progenitor cells., Blood, 90, 3438, 10.1182/blood.V90.9.3438 · DOI · Paper page
  177. Vander Heiden, 2009, Understanding the Warburg effect: the metabolic requirements of cell proliferation., Science, 324, 1029, 10.1126/science.1160809 · DOI · Paper page
  178. Weber, 2008, Anemia and transfusions in patients undergoing surgery for cancer., Ann. Surg. Oncol., 15, 34, 10.1245/s10434-007-9502-9 · DOI
  179. Wish, 2006, Assessing iron status: beyond serum ferritin and transferrin saturation., Clin. J. Am. Soc. Nephrol., 1, S4, 10.2215/CJN.01490506 · DOI · Paper page
  180. Woodson, 1982, Effect of increased oxygen affinity and anemia on cardiac output and its distribution., J. Appl. Physiol., 53, 1299, 10.1152/jappl.1982.53.5.1299 · doi:10.1152/jappl.1982.53.5.1299
  181. Wright, 2007, Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia., J. Clin. Oncol., 25, 1027, 10.1200/JCO.2006.07.1514 · DOI · Paper page
  182. Wu, 2015, Hypoxia-induced autophagy mediates cisplatin resistance in lung cancer cells., Sci. Rep., 5, 10.1038/srep12291 · DOI · Paper page
  183. Xia, 2018, The role of HIF-1α in chemo-/radioresistant tumors., Onco Targets Ther., 11, 3003, 10.2147/OTT.S158206 · DOI · Paper page
  184. Zhang, 2017, Combined prognostic value of pretreatment anemia and cervical node necrosis in patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: a large-scale retrospective study., Cancer Med., 6, 2822, 10.1002/cam4.1233 · DOI
  185. Zhang, 2014, Impact of preoperative anemia on relapse and survival in breast cancer patients., BMC Cancer, 14, 10.1186/1471-2407-14-844 · DOI
  186. Zhu, 2015, Association of pretreatment anemia with pathological response and survival of breast cancer patients treated with neoadjuvant chemotherapy: a population-based study., PLoS One, 10, 10.1371/journal.pone.0136268 · DOI

Cited by

Metadata

Authors
Madeddu, C., Gramignano, G., Astara, G., Demontis, R., Sanna, E., Atzeni, V., & Macciò, A.
Venue
Frontiers in Physiology
Published
2018-09-20
Volume
9
Pages
1294-1294
ISSN
1664-042X (ISSN-L)
OpenAlex
W2889138052
Cited by
201
References
23
FWCI
9.73
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.